Companies: 10,795·Total market cap: $144.5T
Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals, Inc.

RPHMNASDAQHealthcare
$18.20
+$16.47(+952.02%)
Market Cap$60840416
P/E Ratio
52W High$82.9
52W Low$1.68
SEC Filings

Reneo Pharmaceuticals, Inc. (RPHM) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001637715 · RPHM · NASDAQ · as of Jun 9, 2026

Filing snapshot

377
Total Filings
4
Latest Form
2026-06-08
Most Recent
2021
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001637715 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-12
Fiscal Year End
Mar 12, 2026
Accession No.
0001193125-26-104147
Primary Document
okur-20251231.htm
Source: data.sec.gov · CIK 0001637715 · Accession 0001193125-26-104147

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-05
8-KCurrent Report
8-K
2026-06-04Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
S-8Employee Stock Plan Registration
S-8
2026-06-05
View
8-KCurrent Report
8-K
2026-06-04
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-27
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
8-KCurrent Report
8-K
2026-05-05
View
10-QQuarterly Report
10-Q
2026-05-05
View
EFFECTEFFECT
EFFECT
2026-05-04
View
CORRESPCORRESP
CORRESP
2026-04-30
View
UPLOADUPLOAD
UPLOAD
2026-04-30
View
S-3Shelf Registration
S-3
2026-04-24
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-21
View
DEF 14AProxy Statement
DEF 14A
2026-04-21
View
ARSARS
ARS
2026-04-21
View
3Initial Statement of Beneficial Ownership
3
2026-04-07
View
SCHEDULE 13DSCHEDULE 13D
SCHEDULE 13D
2026-04-07
View
Showing 1–15 of 256 filingsForm 4 / 144 hidden· 377 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001637715  |  Exchange: NASDAQ · Healthcare

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) has submitted 377 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001637715, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Reneo Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Reneo Pharmaceuticals, Inc. 10-K was filed on 2026-03-12 for fiscal year ending 2026. Historical RPHM 10-K annual reports are available from 2018 through 2026.

Investors researching Reneo Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

RPHM SEC Filings · 8 questions

Reneo Pharmaceuticals, Inc. (RPHM) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 377 filings and access original documents at no cost. Reneo Pharmaceuticals, Inc.'s CIK is 0001637715.

RPHM SEC filingsReneo Pharmaceuticals, Inc. SEC documentsfind RPHM 10-K